These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 21325073)

  • 1. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.
    Mallon R; Feldberg LR; Lucas J; Chaudhary I; Dehnhardt C; Santos ED; Chen Z; dos Santos O; Ayral-Kaloustian S; Venkatesan A; Hollander I
    Clin Cancer Res; 2011 May; 17(10):3193-203. PubMed ID: 21325073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.
    Mallon R; Hollander I; Feldberg L; Lucas J; Soloveva V; Venkatesan A; Dehnhardt C; Delos Santos E; Chen Z; Dos Santos O; Ayral-Kaloustian S; Gibbons J
    Mol Cancer Ther; 2010 Apr; 9(4):976-84. PubMed ID: 20371716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma.
    Liu T; Sun Q; Li Q; Yang H; Zhang Y; Wang R; Lin X; Xiao D; Yuan Y; Chen L; Wang W
    Mol Cancer Ther; 2015 Feb; 14(2):429-39. PubMed ID: 25504751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
    J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.
    Dehnhardt CM; Venkatesan AM; Chen Z; Delos-Santos E; Ayral-Kaloustian S; Brooijmans N; Yu K; Hollander I; Feldberg L; Lucas J; Mallon R
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4773-8. PubMed ID: 21763134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
    Gazi M; Moharram SA; Marhäll A; Kazi JU
    Cancer Lett; 2017 Apr; 392():9-16. PubMed ID: 28159681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.
    Chang KY; Tsai SY; Wu CM; Yen CJ; Chuang BF; Chang JY
    Clin Cancer Res; 2011 Nov; 17(22):7116-26. PubMed ID: 21976531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
    Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
    Yuan J; Mehta PP; Yin MJ; Sun S; Zou A; Chen J; Rafidi K; Feng Z; Nickel J; Engebretsen J; Hallin J; Blasina A; Zhang E; Nguyen L; Sun M; Vogt PK; McHarg A; Cheng H; Christensen JG; Kan JL; Bagrodia S
    Mol Cancer Ther; 2011 Nov; 10(11):2189-99. PubMed ID: 21750219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.
    Venkatesan AM; Dehnhardt CM; Delos Santos E; Chen Z; Dos Santos O; Ayral-Kaloustian S; Khafizova G; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Yu K; Gibbons J; Abraham RT; Chaudhary I; Mansour TS
    J Med Chem; 2010 Mar; 53(6):2636-45. PubMed ID: 20166697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
    Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
    Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
    Wurz RP; Liu L; Yang K; Nishimura N; Bo Y; Pettus LH; Caenepeel S; Freeman DJ; McCarter JD; Mullady EL; Miguel TS; Wang L; Zhang N; Andrews KL; Whittington DA; Jiang J; Subramanian R; Hughes PE; Norman MH
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5714-20. PubMed ID: 22832322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
    Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
    Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
    Yu K; Shi C; Toral-Barza L; Lucas J; Shor B; Kim JE; Zhang WG; Mahoney R; Gaydos C; Tardio L; Kim SK; Conant R; Curran K; Kaplan J; Verheijen J; Ayral-Kaloustian S; Mansour TS; Abraham RT; Zask A; Gibbons JJ
    Cancer Res; 2010 Jan; 70(2):621-31. PubMed ID: 20068177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.
    Shapiro GI; Bell-McGuinn KM; Molina JR; Bendell J; Spicer J; Kwak EL; Pandya SS; Millham R; Borzillo G; Pierce KJ; Han L; Houk BE; Gallo JD; Alsina M; Braña I; Tabernero J
    Clin Cancer Res; 2015 Apr; 21(8):1888-95. PubMed ID: 25652454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer.
    Ning C; Liang M; Liu S; Wang G; Edwards H; Xia Y; Polin L; Dyson G; Taub JW; Mohammad RM; Azmi AS; Zhao L; Ge Y
    Oncotarget; 2017 Jul; 8(27):44295-44311. PubMed ID: 28574828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
    Dai C; Zhang B; Liu X; Ma S; Yang Y; Yao Y; Feng M; Bao X; Li G; Wang J; Guo K; Ma W; Xing B; Lian W; Xiao J; Cai F; Zhang H; Wang R
    Endocrinology; 2013 Mar; 154(3):1247-59. PubMed ID: 23384836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
    Wallin JJ; Edgar KA; Guan J; Berry M; Prior WW; Lee L; Lesnick JD; Lewis C; Nonomiya J; Pang J; Salphati L; Olivero AG; Sutherlin DP; O'Brien C; Spoerke JM; Patel S; Lensun L; Kassees R; Ross L; Lackner MR; Sampath D; Belvin M; Friedman LS
    Mol Cancer Ther; 2011 Dec; 10(12):2426-36. PubMed ID: 21998291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease.
    Freitag H; Christen F; Lewens F; Grass I; Briest F; Iwaszkiewicz S; Siegmund B; Grabowski P
    Neuroendocrinology; 2017; 105(1):90-104. PubMed ID: 27513674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.